1. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
- Author
-
Geert D'Haens, Brian G. Feagan, Niels Vande Casteele, Silvio Danese, Gregor Novak, Reena Khanna, William J. Sandborn, Pieter Hindryckx, Vipul Jairath, Hindryckx, P, Vande Casteele, N, Novak, G, Khanna, R, D'Haens, G, Sandborn, Wj, Danese, S, Jairath, V, and Feagan, Bg
- Subjects
Drug ,medicine.medical_specialty ,Integrins ,media_common.quotation_subject ,Immunoglobulins ,Vascular Cell Adhesion Molecule-1 ,Disease ,Antibodies, Monoclonal, Humanized ,Inflammatory bowel disease ,Gastroenterology ,Interleukin-23 ,Vedolizumab ,Smad7 Protein ,03 medical and health sciences ,0302 clinical medicine ,Mucoproteins ,Crohn Disease ,Adrenal Cortex Hormones ,Internal medicine ,Ustekinumab ,medicine ,Humans ,Molecular Targeted Therapy ,Intensive care medicine ,Protein Kinase Inhibitors ,media_common ,Janus Kinases ,business.industry ,Tumor Necrosis Factor-alpha ,Advanced stage ,Biosimilar ,General Medicine ,medicine.disease ,Ulcerative colitis ,Interleukin-12 ,digestive system diseases ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Colitis, Ulcerative ,Drug Therapy, Combination ,business ,Cell Adhesion Molecules ,Algorithms ,Immunosuppressive Agents ,medicine.drug - Abstract
The therapeutic landscape for inflammatory bowel disease [IBD] is rapidly evolving. Two new biologic drugs, vedolizumab and ustekinumab, have recently entered the marketplace, the first biosimilars have been introduced, and several other agents are at an advanced stage of clinical development. In parallel, therapeutic goals have shifted from symptom control towards mucosal healing and prevention of bowel damage. In the coming years, gastroenterologists will be faced with unprecedented choices when selecting the best treatment for their patients with IBD. In this article, we review existing data on the mechanisms of action, efficacy, and safety of recently approved and late-stage pipeline therapies, and use this information to speculate on the positioning of these drugs, alone or in combination, in therapeutic algorithms for Crohn's disease and ulcerative colitis.
- Published
- 2017